Celegence

Executive Summary

Celegence, founded in 2015 and based in New York, is a regulatory services and technology company serving the life sciences industry. The company provides AI-empowered solutions for medical writing, regulatory publishing, and compliance, targeting pharmaceutical, medical device, and in-vitro diagnostics manufacturers. By automating documentation processes, Celegence aims to enhance speed, accuracy, and cost-efficiency for its clients, positioning itself as a key enabler in the increasingly complex regulatory landscape. Celegence's proprietary technology platforms offer a compelling value proposition in a market where regulatory timelines and accuracy are critical. With the growing adoption of AI in life sciences and increased regulatory scrutiny, the company is well-positioned for growth. Its focus on both services and technology differentiates it from pure-play consultants or software providers. Future success will depend on continued platform innovation, strategic partnerships, and expansion of its client base. We assign a conviction score of 65, reflecting a solid but not yet fully proven business model with significant addressable market potential.

Upcoming Catalysts (preview)

• Q3 2026Launch of Enhanced AI-Powered Regulatory Publishing Platform70% success
• Q4 2026Strategic Partnership with Major Pharmaceutical Company60% success
• TBDExpansion into European Regulatory Market50% success